290b89f5-2a44-424b-b77d-a190dcb93e07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 81
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.410
- MYOGENESIS+0.390
- APICAL_JUNCTION+0.360
- APICAL_SURFACE+0.350
- NOTCH_SIGNALING+0.350
- HEDGEHOG_SIGNALING+0.340
- XENOBIOTIC_METABOLISM+0.290
- CHOLESTEROL_HOMEOSTASIS+0.280
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.270
- ADIPOGENESIS+0.250
Top 10 suppressed
- PROTEIN_SECRETION-0.470
- INTERFERON_ALPHA_RESPONSE-0.400
- INTERFERON_GAMMA_RESPONSE-0.350
- ANDROGEN_RESPONSE-0.330
- E2F_TARGETS-0.320
- G2M_CHECKPOINT-0.320
- IL6_JAK_STAT3_SIGNALING-0.290
- TNFA_SIGNALING_VIA_NFKB-0.230
- ALLOGRAFT_REJECTION-0.210
- UV_RESPONSE_DN-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | c0054cf0-8f4b-47b6-a8fc-63a1fd36bcc7 | — | — | 0.890 |
| 2 | a8235ad1-0c5f-4a0b-b595-85ef3a1e49ff | — | — | 0.888 |
| 3 | 44f9e45d-d779-4865-8f10-d085d5d25447 | — | — | 0.872 |
| 4 | 1e82995c-f318-4225-96d4-f1e98bcbf60b | — | — | 0.869 |
| 5 | 05167d53-0b47-4131-bfa4-450b236b9fd5 | — | — | 0.848 |
| 6 | 59364db9-7bf7-4a15-9798-8e3886078012 | — | — | 0.842 |
| 7 | a4322796-9189-48c2-9e7c-7b1493b5799a | — | — | 0.836 |
| 8 | 40b92a76-f324-4cdd-8209-517d021acd47 | — | — | 0.827 |
| 9 | f0f41799-29e8-43f9-b357-722df163e963 | — | — | 0.815 |
| 10 | 299f36bd-d9fd-41f5-8a29-3382e147a14f | — | — | 0.810 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.410 | Inavolisib | — uncovered |
| MYOGENESIS | 0.390 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.360 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.350 | Temsirolimus | — uncovered |
| NOTCH_SIGNALING | 0.350 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.340 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.290 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.280 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.270 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.250 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.250 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.240 | Remibrutinib | — uncovered |
| COAGULATION | 0.240 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.220 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.220 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.210 | Cobimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.190 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.190 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.160 | Idelalisib | — uncovered |